Oncology Medical News

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

A phase II, randomized, controlled, double-blinded trial of weekly elesclomol plus paclitaxel versus paclitaxel alone for stage IV metastatic melanoma
Journal of Clinical Oncology, 10/19/09

O'Day S et al. – E + P resulted in a statistically significant doubling of median PFS, with an acceptable toxicity profile and encouraging OS. A multinational, phase III trial (SYMMETRY) of E + P compared with paclitaxel alone in metastatic melanoma has closed.

Methods

Randomly assigned patients with metastatic melanoma, measurable disease, and one or fewer prior chemotherapy regimens to elesclomol 213 mg/m2 plus paclitaxel 80 mg/m2 (E + P) or to paclitaxel 80 mg/m2 alone at a 2:1 ratio
Regimens were given as 1-hour intravenous infusion weekly, during 3 of every 4 weeks until disease progression per Response Evaluation Criteria in Solid Tumors or death occurred
Patients who experienced progression were unblended, and patients on paclitaxel alone permitted to cross over to E + P
Primary efficacy end point progression-free survival (PFS)
Secondary end points response rate (RR), toxicity, and overall survival

Results

At 21 US sites, 53 patients randomly assigned to E + P, and 28 patients randomly assigned to paclitaxel
Addition of elesclomol to paclitaxel yielded doubling of median PFS (112 v 56 days) and 41.7% risk reduction for disease progression/death
Respective RRs for E + P and paclitaxel groups were 15% and 3%; median OS was 11.9 v 7.8 months
Of patients on paclitaxel alone, 19 [68%] of 28 crossed over to E + P after progression
Weekly E + P well tolerated

<< Previous
Prognostic and predictive factors in a randomized phase III trial...

Next >>
A randomized, phase III multicenter trial of gemcitabine in...